Johnson & Johnson (JNJ) Receives FDA Complete Response Letter on XARELTO
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $149.56 +0.30%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 3.3%
EPS Growth %: +1.1%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 3.3%
EPS Growth %: +1.1%
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) disclosed that its Janssen Research & Development, LLC unit received a U.S. Food and Drug Administration (FDA) complete response letter for the supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS).
"We remain confident in the results of the ATLAS ACS 2 TIMI 51 trial and are in ongoing discussions with the FDA regarding this sNDA," said Dr. Christopher Nessel, Vice President, Cardiovascular Franchise Medical Leader at Janssen.
"We remain confident in the results of the ATLAS ACS 2 TIMI 51 trial and are in ongoing discussions with the FDA regarding this sNDA," said Dr. Christopher Nessel, Vice President, Cardiovascular Franchise Medical Leader at Janssen.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Johnson & Johnson (JNJ) to Buy, 'Steady outlook, low expectations'
- Novartis (NVS) Announces FDA Approval of Lutathera
- Day One Biopharmaceuticals' (DAWN) OJEMDA Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
